SEC Form 4 · accession 0001209191-15-082293
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William K Heiden
Director
Period of report
Nov 23, 2015
Accepted (ET)
Nov 25, 2015 · 6:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)F1 | $34.98 | Nov 23, 2015 | A | 15,500 | A | — | Nov 22, 2022 | Common Stock | 15,500 | 15,500 | D |
Explanation of responses
- F11/3 of the shares shall vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continuous service.